Generic Name and Formulations:
Acetylcysteine 0.5g, 2.5g; effervescent tabs for oral soln; lemon-mint flavor; contains sodium bicarbonate.
Arbor Pharmaceuticals, LLC
Indications for CETYLEV:
To minimize hepatic injury after acetaminophen overdose in patients with acute ingestion or from repeated supratherapeutic ingestion (RSI).
Adults and Children:
Acute ingestion: assess history and timing of acetaminophen ingestion and obtain serum acetaminophen level at least 4hrs post-ingestion. If time of ingestion is unknown: give loading dose immediately and obtain acetaminophen level to determine need for continued treatment. If serum acetaminophen level unobtainable within 8hr interval or if toxicity evident: give loading dose immediately then continue for a total of 17 doses. If >8hrs post-ingestion and time of ingestion is known, give loading dose immediately and obtain acetaminophen level to determine need for continued treatment. If <8hrs post-ingestion and time of ingestion and the acetaminophen level are known, plot level on Rumack-Matthew nomogram to determine whether or not to initiate treatment (see full labeling). Loading dose: 140mg/kg. Maintenance dose: 70mg/kg every 4hrs for a total of 17 doses. May be administered by nasoduodenal tube or can consider IV form if unable to retain Cetylev. For weight-based dosage and others: see full labeling. RSI: obtain acetaminophen level and other lab tests for guidance; or, contact regional poison center.
Discontinue if hypersensitivity reactions occur unless necessary and reactions can be controlled. Risk of upper GI hemorrhage risk in those with esophageal varices or peptic ulcers. Monitor AST, ALT, bilirubin, INR, creatinine, BUN, blood glucose, electrolytes. CHF, hypertension, renal impairment: consider total sodium intake. Pregnancy. Nursing mothers.
Nausea, vomiting, other GI symptoms, rash with/without fever; upper GI hemorrhage.
Tabs—2x10 (blister packs)
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Breast Cancer Screening Recommendations Not Completely Reflective of Race, Age
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|